Argenica Widens Half-Year Loss as ARG-007 Stroke Trial Spending Climbs

Argenica Therapeutics Ltd ( (AU:AGN) ) has shared an update.

Argenica Therapeutics reported a sharp increase in half-year loss to $3.8 million as it accelerated clinical and development spending on its neuroprotective drug pipeline. Revenue fell 77% to $720,169, primarily due to timing differences in recognition of the Australian R&D tax incentive rebate, while net tangible assets per share dropped to 2.68 cents.

Research and development expenses rose to $3.0 million, driven mainly by the Phase 2 trial of ARG-007 in ischemic stroke patients and other non-clinical studies. Net operating cash outflows widened to $5.5 million despite non-dilutive government grant and R&D rebate inflows, and the company ended the period with $5.0 million in cash and no interim dividend, underscoring ongoing funding needs as it advances its clinical program.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.64 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is an Australian biotechnology company focused on developing neuroprotective therapeutic drugs. Its lead candidate, ARG-007, is being advanced through clinical development for ischemic stroke, alongside non-clinical studies exploring additional neurological indications, supported in part by government R&D funding programs.

Average Trading Volume: 211,505

Technical Sentiment Signal: Sell

Current Market Cap: A$34.04M

Find detailed analytics on AGN stock on TipRanks’ Stock Analysis page.